Technical Analysis for 0H22 - Bioinvent International AB

Grade Last Price % Change Price Change
F 28.30 0.00% 0.00
0H22 closed unchanged on Friday, April 21, 2023, on 0 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction -1.65%
Shooting Star Candlestick Bearish -5.67%
Narrow Range Bar Range Contraction -5.67%
Doji - Bearish? Reversal -5.67%
Stochastic Buy Signal Bullish 3.85%
Narrow Range Bar Range Contraction 3.85%
Narrow Range Bar Range Contraction 4.24%
New 52 Week Closing Low Bearish 7.40%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bioinvent International AB Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.


Keywords: Cancer Clinical Medicine Drugs Tumor Antibodies Monoclonal Antibodies Treatment Of Cancer Breakthrough Therapy Cancer Treatments Antineoplastic Drugs Bristol Myers Squibb Solid Tumors

Is 0H22 a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 48.575
52 Week Low 26.35
Average Volume 287,896
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 35.20
10-Day Moving Average 28.83
Average True Range 2.11
RSI (14) 0.00
ADX 0.0
+DI 30.12
-DI 57.26
Chandelier Exit (Long, 3 ATRs) 42.25
Chandelier Exit (Short, 3 ATRs) 32.68
Upper Bollinger Bands 50.06
Lower Bollinger Band 20.33
Percent B (%b) 0.27
BandWidth 84.49
MACD Line -5.25
MACD Signal Line -4.22
MACD Histogram -1.0297
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.60
Resistance 3 (R3) 28.57 28.43 28.55
Resistance 2 (R2) 28.43 28.36 28.45 28.53
Resistance 1 (R1) 28.37 28.31 28.40 28.40 28.52
Pivot Point 28.23 28.23 28.25 28.25 28.23
Support 1 (S1) 28.17 28.16 28.20 28.20 28.08
Support 2 (S2) 28.03 28.11 28.05 28.07
Support 3 (S3) 27.97 28.03 28.05
Support 4 (S4) 28.00